

CURRICULUM VITAE

Girolamo CALÒ

University of Padova
Department of Pharmaceutical and Pharmacological Sciences
Largo Meneghetti, 2
35131 Padova
e-mail: girolamo.calò@unipd.it

Date of Birth: March 27th 1965
Nationality: Italian
Family status: Married, 3 childrens

Education:

Laurea in Medicina e Chirurgia (MD), 30 Ottobre 1989, Università degli studi di Ferrara, Ferrara (110/110 e la lode) (Equivalent of First Degree in Medicine and Surgery)

Dottore di Ricerca (Ph.D.). Dottorato di ricerca in Farmacologia Cellulare e Molecolare, Ottobre 1995, Università degli studi di Ferrara.

Employment:

Full Professor of Pharmacology, Dept. Pharmaceutical and Pharmacological Sciences, University of Padova (Dec 2020 –).

Associate Professor of Pharmacology, Dept. Medical Sciences, Section of Pharmacology, University of Ferrara (Nov 2014 – Nov 2020).

Assistant Professor of Pharmacology, Dept. Medical Sciences, Section of Pharmacology, University of Ferrara (Sept 1995 – Oct 2014).

Personal Statement

G. Calò' has a large experience in research with a broad background in the pharmacology of peptidergic systems. Since 1990 G. Calò' has published > 280 papers (number of citations > 9500, H number 50) focused on peptide receptor pharmacology in particular in the fields of kinins, tachykinins, endothelins, opioids, nociceptin/orphanin FQ, urotensin II, and neuropeptide S. Several of these papers, particularly in the field of nociceptin/orphanin FQ and neuropeptide S, have been highly quoted placing them in the top 1% within their field: according to essential science indicators this demonstrated that the work summarized in those papers was highly influential and made a significant impact among scientists working in the field. G. Calò' is also author of several patents on original ligands for GPCR and novel therapeutic indications for such ligands. Since 1999 G. Calò' received research grants from different institutions at local, national, european, and international levels, and performed a large number of projects in collaboration with pharma industries.

Girolamo Calò'

